Skip to main content

Clinical Trials Using Yttrium Y 90 Glass Microspheres

Review the clinical trials studying yttrium y 90 glass microspheres on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-6 of 6

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Status: Active
Location: 13 locations
Immunotherapy (Tebentafusp) and Radiation Therapy (Yttrium-90 Radioembolization) for the Treatment of Uveal Melanoma Metastatic to the Liver
Status: Active
Location: 8 locations
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Status: Active
Location: 4 locations
Radiation Treatment (Therasphere) in Combination with Systemic Therapy for the Treatment of Advanced Hepatocellular Carcinoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
Status: Temporarily Closed to Accrual
Location: Northwestern University, Chicago, Illinois